标题
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-09-28
DOI
10.1038/nrd.2018.136
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype
- (2018) Georgia Minakaki et al. Autophagy
- The concept of alpha-synuclein as a prion-like protein: ten years after
- (2018) Jennifer A. Steiner et al. CELL AND TISSUE RESEARCH
- Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives
- (2018) Jin-Sung Park et al. Current Neurology and Neuroscience Reports
- Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications
- (2018) Manuela Mellone et al. JOURNAL OF NEURAL TRANSMISSION
- Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
- (2018) S. Pablo Sardi et al. MOVEMENT DISORDERS
- Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
- (2018) Anthony E. Lang et al. MOVEMENT DISORDERS
- Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide
- (2018) Friederike Zunke et al. NEURON
- mGlu 4 allosteric modulation for treating Parkinson's disease
- (2018) Delphine Charvin NEUROPHARMACOLOGY
- GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers
- (2018) Sangjune Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
- (2018) Xian-Si Zeng et al. Frontiers in Aging Neuroscience
- Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
- (2018) Veronica Ghiglieri et al. Frontiers in Neurology
- LRRK2 activation in idiopathic Parkinson’s disease
- (2018) Roberto Di Maio et al. Science Translational Medicine
- Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
- (2017) Andrew B. West EXPERIMENTAL NEUROLOGY
- Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification
- (2017) Wai Kin D. Ko et al. EXPERIMENTAL NEUROLOGY
- Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
- (2017) Ramón Cacabelos INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4
- (2017) Delphine Charvin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Non-human primate models of PD to test novel therapies
- (2017) Marc Morissette et al. JOURNAL OF NEURAL TRANSMISSION
- Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease
- (2017) Karamjeet Kaur et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Therapies targeting DNA and RNA in Huntington's disease
- (2017) Edward J Wild et al. LANCET NEUROLOGY
- Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study
- (2017) Anette Schrag et al. LANCET NEUROLOGY
- Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
- (2017) Tim E. Moors et al. Molecular Neurodegeneration
- Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins
- (2017) C. Warren Olanow et al. MOVEMENT DISORDERS
- Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
- (2017) J.A. Obeso et al. MOVEMENT DISORDERS
- The two-century journey of Parkinson disease research
- (2017) Serge Przedborski NATURE REVIEWS NEUROSCIENCE
- Inhibitory Basal Ganglia Inputs Induce Excitatory Motor Signals in the Thalamus
- (2017) Jeongjin Kim et al. NEURON
- Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research
- (2017) Nadhir Litim et al. NEUROPHARMACOLOGY
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies
- (2017) Mathieu Bourdenx et al. PROGRESS IN NEUROBIOLOGY
- Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
- (2017) Laurie K. Mischley et al. Journal of Parkinsons Disease
- Is Exenatide a Treatment for Parkinson’s Disease?
- (2017) Dilan Athauda et al. Journal of Parkinsons Disease
- Glucocerebrosidase Mutations in Parkinson Disease
- (2017) Grace O’Regan et al. Journal of Parkinsons Disease
- The MPTP Story
- (2017) J. William Langston Journal of Parkinsons Disease
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance
- (2017) Paolo Remondelli et al. Frontiers in Molecular Neuroscience
- The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease
- (2017) Erica L. Gorenberg et al. Frontiers in Neuroscience
- Mitophagy in Parkinson’s Disease: Pathogenic and Therapeutic Implications
- (2017) Fei Gao et al. Frontiers in Neurology
- Parkinson disease
- (2017) Werner Poewe et al. Nature Reviews Disease Primers
- Levodopa in Parkinson’s Disease: Current Status and Future Developments
- (2017) Nicola Tambasco et al. Current Neuropharmacology
- Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson’s disease
- (2017) Caroline J. Zeiss et al. PLoS One
- Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial
- (2017) Agnieszka Ciesielska et al. PLoS One
- Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review
- (2016) A. D. Andersen et al. ACTA NEUROLOGICA SCANDINAVICA
- Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice
- (2016) Anna Migdalska-Richards et al. ANNALS OF NEUROLOGY
- A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
- (2016) David J. M. McGhee et al. BMC Neurology
- Ade novocompound targeting α-synuclein improves deficits in models of Parkinson’s disease
- (2016) Wolfgang Wrasidlo et al. BRAIN
- New concepts in the pathogenesis and presentation of Parkinsons disease
- (2016) A. Sauerbier et al. CLINICAL MEDICINE
- Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
- (2016) Robert A. Hauser et al. CLINICAL NEUROPHARMACOLOGY
- Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors
- (2016) Stephen M. Stahl CNS SPECTRUMS
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
- (2016) Dilan Athauda et al. DRUG DISCOVERY TODAY
- Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
- (2016) Dhanya Vijayakumar et al. DRUGS
- The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study
- (2016) K. M. Prakash et al. EUROPEAN JOURNAL OF NEUROLOGY
- The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study
- (2016) R. Erro et al. EUROPEAN JOURNAL OF NEUROLOGY
- The relationship between glucocerebrosidase mutations and Parkinson disease
- (2016) Anna Migdalska-Richards et al. JOURNAL OF NEUROCHEMISTRY
- Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
- (2016) Abdel A. Belaidi et al. JOURNAL OF NEUROCHEMISTRY
- Mitochondrial dysfunction in Parkinson's disease
- (2016) Anindita Bose et al. JOURNAL OF NEUROCHEMISTRY
- Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication
- (2016) Seongyeol Park et al. JOURNAL OF NUCLEAR MEDICINE
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson’s Disease
- (2016) Junjun Zhao et al. MOLECULAR NEUROBIOLOGY
- CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
- (2016) John Marshall et al. MOLECULAR THERAPY
- Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment
- (2016) Anthony H.V. Schapira et al. MOVEMENT DISORDERS
- A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
- (2016) François Tison et al. MOVEMENT DISORDERS
- Oscillatory activity in the basal ganglia and deep brain stimulation
- (2016) Jorge Guridi et al. MOVEMENT DISORDERS
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers
- (2016) Dale B. Schenk et al. MOVEMENT DISORDERS
- Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
- (2016) Patrick P. Michel et al. NEURON
- An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models
- (2016) Wai Kin D. Ko et al. NEUROPHARMACOLOGY
- Challenges in detecting disease modification in Parkinson's disease clinical trials
- (2016) Dilan Athauda et al. PARKINSONISM & RELATED DISORDERS
- Insulin resistance and Parkinson’s disease: A new target for disease modification?
- (2016) D. Athauda et al. PROGRESS IN NEUROBIOLOGY
- Alpha-synuclein-based models of Parkinson's disease
- (2016) B. Dehay et al. REVUE NEUROLOGIQUE
- Optimizing Transgene Configuration and Protein Fusions to Maximize Dopamine Production for the Gene Therapy of Parkinson's Disease
- (2016) Hannah J. Stewart et al. Human Gene Therapy Clinical Development
- Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
- (2016) James B. Koprich et al. PLoS One
- Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
- (2015) C. Warren Olanow et al. ANNALS OF NEUROLOGY
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
- (2015) Tomoyoshi Kondo et al. CLINICAL NEUROPHARMACOLOGY
- Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease
- (2015) Marianne Amalric CURRENT OPINION IN PHARMACOLOGY
- Parkinson’s disease: a review of non-motor symptoms
- (2015) Abdul Qayyum Rana et al. Expert Review of Neurotherapeutics
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
- (2015) LANCET NEUROLOGY
- Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity
- (2015) Giovanna Paolone et al. MOVEMENT DISORDERS
- Advances in clinical trials for movement disorders
- (2015) Karl Kieburtz et al. MOVEMENT DISORDERS
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
- (2015) Rajesh Pahwa et al. MOVEMENT DISORDERS
- Balancing the basal ganglia circuitry: A possible new role for dopamine D2 receptors in health and disease
- (2015) Maxime Cazorla et al. MOVEMENT DISORDERS
- Proteostasis and aging
- (2015) Susmita Kaushik et al. NATURE MEDICINE
- Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells
- (2015) Giulia Ambrosi et al. NEUROBIOLOGY OF DISEASE
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
- (2015) Reina N. Fuji et al. Science Translational Medicine
- Peripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects
- (2015) David K. Simon et al. Journal of Parkinsons Disease
- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- The Synaptic Function of α-Synuclein
- (2015) Jacqueline Burré Journal of Parkinsons Disease
- Parkinson’s disease: a review of non-motor symptoms
- (2015) Abdul Qayyum Rana et al. Expert Review of Neurotherapeutics
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
- (2015) Robert A. Hauser et al. JAMA Neurology
- Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression
- (2015) Mathieu Bourdenx et al. Acta Neuropathologica Communications
- Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials
- (2014) Markus Mandler et al. ACTA NEUROPATHOLOGICA
- Prioritized research recommendations from the National Institute of Neurological Disorders and StrokeParkinson'sDisease 2014 conference
- (2014) Beth-Anne Sieber et al. ANNALS OF NEUROLOGY
- Novel levodopa formulations in the treatment of Parkinson's disease
- (2014) Manuela Pilleri et al. Expert Review of Neurotherapeutics
- Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
- (2014) D. Games et al. JOURNAL OF NEUROSCIENCE
- Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
- (2014) Stéphane Palfi et al. LANCET
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
- (2014) Robert A Hauser et al. LANCET NEUROLOGY
- The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model
- (2014) Erwan Bezard et al. MOVEMENT DISORDERS
- Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
- (2014) Mike A Nalls et al. NATURE GENETICS
- Functional connectivity in the basal ganglia network differentiates PD patients from controls
- (2014) K. Szewczyk-Krolikowski et al. NEUROLOGY
- Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
- (2014) Olivier Rascol et al. PARKINSONISM & RELATED DISORDERS
- Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs
- (2014) Thomas J. Moore et al. JAMA Internal Medicine
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
- (2014) et al. JAMA Neurology
- Emerging Candidate Biomarkers for Parkinson’s Disease: a Review
- (2014) Enrico Saracch Aging and Disease
- Convergence of dopamine and glutamate signaling onto striatal ERK activation in response to drugs of abuse
- (2014) Emma Cahill et al. Frontiers in Pharmacology
- Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates
- (2014) Nicolas Morin et al. Frontiers in Neurology
- Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate
- (2014) Waldy San Sebastian et al. Molecular Therapy-Methods & Clinical Development
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
- (2013) Jens Wagner et al. ACTA NEUROPATHOLOGICA
- Glucocerebrosidase mutations and the pathogenesis of Parkinson disease
- (2013) Michelle S. Beavan et al. ANNALS OF MEDICINE
- Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
- (2013) David Devos et al. ANTIOXIDANTS & REDOX SIGNALING
- Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson’s disease and Parkinson’s disease psychosis
- (2013) David Hubbard et al. BEHAVIOURAL PHARMACOLOGY
- Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
- (2013) Susan H. Fox DRUGS
- Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators
- (2013) Orly Weinreb et al. FREE RADICAL BIOLOGY AND MEDICINE
- Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration
- (2013) Jee-Won Sul et al. HUMAN MOLECULAR GENETICS
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
- (2013) Raymond T Bartus et al. MOLECULAR THERAPY
- Concurrent activation of striatal direct and indirect pathways during action initiation
- (2013) Guohong Cui et al. NATURE
- Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease
- (2013) Laura Dunn et al. NEUROBIOLOGY OF AGING
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys
- (2013) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
- (2013) Daniel Ness et al. PLoS One
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
- (2013) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease
- (2013) Eleftheria K. Pissadaki et al. Frontiers in Computational Neuroscience
- Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
- (2012) Susan Duty CNS DRUGS
- Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
- (2012) Gabriele Mittermeyer et al. HUMAN GENE THERAPY
- NADPH Oxidase 1 Mediates -Synucleinopathy in Parkinson's Disease
- (2012) A. C. Cristovao et al. JOURNAL OF NEUROSCIENCE
- Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
- (2012) Caroline Moreau et al. LANCET NEUROLOGY
- Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
- (2012) Maria Xilouri et al. MOLECULAR NEUROBIOLOGY
- Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies
- (2012) Erwan Bezard et al. MOVEMENT DISORDERS
- Living on the edge with too many mouths to feed: Why dopamine neurons die
- (2012) J. Paul Bolam et al. MOVEMENT DISORDERS
- The many faces of α-synuclein: from structure and toxicity to therapeutic target
- (2012) Hilal A. Lashuel et al. NATURE REVIEWS NEUROSCIENCE
- Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
- (2012) David N. Hauser et al. NEUROBIOLOGY OF DISEASE
- -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
- (2012) M. Decressac et al. Science Translational Medicine
- Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinsonʼs disease
- (2011) Krista McFarland et al. BEHAVIOURAL PHARMACOLOGY
- The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
- (2011) Christine R Swanson et al. Journal of Neuroinflammation
- Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease
- (2011) S. Z. Imam et al. JOURNAL OF NEUROSCIENCE
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- (2011) Robert A Hauser et al. LANCET NEUROLOGY
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease
- (2011) D.J. Surmeier et al. NEUROSCIENCE
- The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys
- (2011) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
- (2011) Eliezer Masliah et al. PLoS One
- Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
- (2010) Robert A. Hodgson et al. EXPERIMENTAL NEUROLOGY
- Are synucleinopathies prion-like disorders?
- (2010) Elodie Angot et al. LANCET NEUROLOGY
- Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry
- (2010) Alexxai V. Kravitz et al. NATURE
- Prion-like transmission of protein aggregates in neurodegenerative diseases
- (2010) Patrik Brundin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
- (2010) K. A. Chung et al. NEUROLOGY
- Metabotropic glutamate receptors: From the workbench to the bedside
- (2010) F. Nicoletti et al. NEUROPHARMACOLOGY
- α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
- (2010) Alison L. McCormack et al. PLoS One
- Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function
- (2010) H. S. Ko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors
- (2010) H. S. Bateup et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mitochondrial dysfunction in Parkinson's disease
- (2009) Konstanze F. Winklhofer et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Combination therapy with Coenzyme Q10and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases
- (2009) Lichuan Yang et al. JOURNAL OF NEUROCHEMISTRY
- Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV -Synucleinopathy
- (2009) C. Y. Chung et al. JOURNAL OF NEUROSCIENCE
- Axonal Transport Defects in Neurodegenerative Diseases
- (2009) G. A. Morfini et al. JOURNAL OF NEUROSCIENCE
- Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
- (2009) Dennis W Dickson et al. LANCET NEUROLOGY
- Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
- (2009) Robert A. Hauser et al. MOVEMENT DISORDERS
- D2R striatopallidal neurons inhibit both locomotor and drug reward processes
- (2009) Pierre F Durieux et al. NATURE NEUROSCIENCE
- Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF
- (2009) M.E. Emborg et al. NEUROBIOLOGY OF DISEASE
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
- (2009) Herbert Y Meltzer et al. NEUROPSYCHOPHARMACOLOGY
- Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia
- (2009) B. Jarraya et al. Science Translational Medicine
- Treatment of imbalance with varenicline (Chantix®): report of a patient with fragile X tremor/ataxia syndrome
- (2008) T. A. Zesiewicz et al. ACTA NEUROLOGICA SCANDINAVICA
- Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started